Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ITV 1

Next Previous
Drug Profile

ITV 1

Alternative Names: Immune therapeutic vaccine-1; ImmunH; Inactivated pepsin fraction HIV vaccine; IPF-ITV Phases; IPF-ITV-1; Irreversible pepsin fraction HIV vaccine; ITV-1

Latest Information Update: 24 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Immunotech Laboratories
  • Class AIDS vaccines; Antivirals; Peptide vaccines
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase II Hepatitis C

Most Recent Events

  • 24 Sep 2020 Launched for HIV infections in Bulgaria (Parenteral) before September 2020 (Immunotech Laboratories website, September 2020)
  • 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in HIV-infections in South Africa (Parenteral, Suspension)
  • 22 Jun 2017 Immunotech Laboratories anticipates to complete the validation documentation and registration process for the manufacture of ITV 1 and submit an application to the Bulgarian Drug Administration by the end of September 2017
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top